JP2023553976A5 - - Google Patents
Info
- Publication number
- JP2023553976A5 JP2023553976A5 JP2023535631A JP2023535631A JP2023553976A5 JP 2023553976 A5 JP2023553976 A5 JP 2023553976A5 JP 2023535631 A JP2023535631 A JP 2023535631A JP 2023535631 A JP2023535631 A JP 2023535631A JP 2023553976 A5 JP2023553976 A5 JP 2023553976A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- composition
- component
- cancer
- urinary tract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063124111P | 2020-12-11 | 2020-12-11 | |
| US63/124,111 | 2020-12-11 | ||
| PCT/IB2021/061499 WO2022123480A1 (en) | 2020-12-11 | 2021-12-09 | Material and method for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023553976A JP2023553976A (ja) | 2023-12-26 |
| JP2023553976A5 true JP2023553976A5 (enExample) | 2024-12-13 |
Family
ID=78916713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023535631A Pending JP2023553976A (ja) | 2020-12-11 | 2021-12-09 | がんを治療するための材料及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12336979B2 (enExample) |
| EP (1) | EP4259093B1 (enExample) |
| JP (1) | JP2023553976A (enExample) |
| KR (1) | KR20230118632A (enExample) |
| CA (1) | CA3201129A1 (enExample) |
| WO (1) | WO2022123480A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10471150B2 (en) | 2010-01-20 | 2019-11-12 | Urogen Pharma Ltd. | Material and method for treating internal cavities |
| CA3201129A1 (en) | 2020-12-11 | 2022-06-16 | Yulia HIONIDI | Material and method for treating cancer |
| WO2024069239A1 (en) * | 2022-09-28 | 2024-04-04 | Urogen Pharma Ltd. | Compositions comprising a thermoreversible hydrogel, and having an extended in-use period |
| KR20260012228A (ko) * | 2023-05-16 | 2026-01-26 | 우로젠 파마 엘티디. | 체강의 면역조절 치료 |
| AU2024301406A1 (en) | 2023-07-25 | 2026-02-12 | Urogen Pharma Ltd. | Treatment of low-grade intermediate-risk non-muscle invasive bladder cancer with a thermally gelling pharmaceutical composition containing mitomycin |
| CN121729785A (zh) | 2023-09-06 | 2026-03-24 | 株式会社Lg新能源 | 袋用片材、袋型电池盒以及用于制造电池盒的方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0386960A3 (en) | 1989-03-07 | 1991-10-23 | American Cyanamid Company | Pharmaceutical compositions useful as drug delivery vehicles and/or as wound dressings |
| US5861174A (en) | 1996-07-12 | 1999-01-19 | University Technology Corporation | Temperature sensitive gel for sustained delivery of protein drugs |
| US6286513B1 (en) | 1998-10-22 | 2001-09-11 | Jessie L. Au | Methods for treating superficial bladder carcinoma |
| US20040009212A1 (en) | 2002-01-30 | 2004-01-15 | Pharma Power Biotec Co. Ltd. | Mucoadhesive thermoresponsive medicament-carrier composition |
| GB0328060D0 (en) | 2003-12-04 | 2004-01-07 | Sod Conseils Rech Applic | Botulinum toxin treatment |
| GB0414825D0 (en) | 2004-07-02 | 2004-08-04 | Biostatus Ltd | Gel formulations and uses thereof |
| WO2007134132A2 (en) | 2006-05-12 | 2007-11-22 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors |
| US9107815B2 (en) | 2008-02-22 | 2015-08-18 | Allergan, Inc. | Sustained release poloxamer containing pharmaceutical compositions |
| JP2011528275A (ja) | 2008-07-17 | 2011-11-17 | ミセル テクノロジーズ，インク． | 薬物送達医療デバイス |
| US10471150B2 (en) | 2010-01-20 | 2019-11-12 | Urogen Pharma Ltd. | Material and method for treating internal cavities |
| WO2011089604A2 (en) * | 2010-01-20 | 2011-07-28 | Theracoat Ltd | Material and method for treating internal cavities |
| WO2013011504A1 (en) * | 2011-07-20 | 2013-01-24 | Theracoat Ltd. | Materials and method for treating internal body cavities |
| EP2734557B1 (en) | 2011-07-20 | 2022-09-07 | UroGen Pharma Ltd. | Production of thermoreversible hydrogels for therapeutic applications |
| ES2648367T3 (es) | 2013-10-22 | 2018-01-02 | Medac Gesellschaft für klinische Spezialpräparate mbH | Procedimiento de preparación de una composición farmacéutica liofilizada que contiene mitomicina C |
| US9801854B1 (en) * | 2014-01-17 | 2017-10-31 | Urogen Pharma Ltd. | Slow release formulations of cell cycle regulators and anti-cancer agents for local treatment of solid cancer |
| US20170136127A1 (en) | 2014-07-01 | 2017-05-18 | Vicus Therapeutics, Llc | Hydrogels for treating and ameliorating cancers and potentiating the immune system and methods of making and using them |
| WO2017083717A1 (en) | 2015-11-11 | 2017-05-18 | Qrono, Inc. | Sustained release pharmaceutical compositions and methods of use |
| EP3532505A4 (en) * | 2016-10-25 | 2019-12-25 | Urogen Pharma Ltd. | BODY CAVES IMMUNODULATING TREATMENTS |
| WO2018169960A1 (en) | 2017-03-17 | 2018-09-20 | The Johns Hopkins University | Nanoparticle formulations for enhanced drug delivery to the bladder |
| EP3498270A1 (en) * | 2017-10-30 | 2019-06-19 | Urogen Pharma Ltd. | Slow release formulations of cell cycle regulators and anti-cancer agents for local treatment of solid cancer |
| CA3201129A1 (en) | 2020-12-11 | 2022-06-16 | Yulia HIONIDI | Material and method for treating cancer |
-
2021
- 2021-12-09 CA CA3201129A patent/CA3201129A1/en active Pending
- 2021-12-09 EP EP21824683.3A patent/EP4259093B1/en active Active
- 2021-12-09 KR KR1020237023151A patent/KR20230118632A/ko active Pending
- 2021-12-09 US US17/546,204 patent/US12336979B2/en active Active
- 2021-12-09 JP JP2023535631A patent/JP2023553976A/ja active Pending
- 2021-12-09 WO PCT/IB2021/061499 patent/WO2022123480A1/en not_active Ceased
-
2023
- 2023-12-11 US US18/535,108 patent/US12171747B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023553976A5 (enExample) | ||
| EP2734557B1 (en) | Production of thermoreversible hydrogels for therapeutic applications | |
| JP2022101549A (ja) | Ｌ－オルニチンフェニルアセテート製剤 | |
| CN102231976B (zh) | 具有脱模剂的奥曲肽植入物 | |
| CN102036656A (zh) | 含有蜡的缓释制剂 | |
| EP4259093B1 (en) | Material and method for treating cancer | |
| JP2010532746A (ja) | 放出調節医薬組成物およびその製造方法 | |
| KR20010075695A (ko) | 신규한 방출 조절된 비이드, 이의 제조 방법 및 이를포함한 다중 유닛 제형 | |
| CN103118662A (zh) | 制备冻干速溶多相剂型的方法 | |
| EP3146962A1 (en) | Allisartan isoproxil solid dispersion and pharmaceutical composition thereof | |
| JP2024522779A (ja) | マクロライドの非ナノ粒子適用形態 | |
| WO2016000608A1 (zh) | 一种阿利沙坦酯固体分散体及含有该固体分散体的药物组合物 | |
| JP2002542290A (ja) | ８−イソオキサゾール−２−アミノテトラリン誘導体を含有する新規医薬組成物 | |
| CN102753146B (zh) | 可经口施用的表皮生长因子药物小丸 | |
| CN1630511A (zh) | 表现出s形曲线模式控释的依来曲帕滕颗粒组合物 | |
| JP2011521942A (ja) | ユーフォルビア・プロストラータを含有する組成物およびその調製方法 | |
| CN1235590C (zh) | 非那甾胺醇质体凝胶制剂 | |
| WO2024220974A1 (en) | Rimegepant fast-dissolving films for oral administration | |
| JP7396598B2 (ja) | 皮膚創傷用組成物 | |
| CN114533690A (zh) | 含抗凝血药物西洛他唑的新制剂及其制备方法 | |
| US20240100019A1 (en) | Compositions comprising a thermoreversible hydrogel, and having an extended in-use period | |
| CN118001259B (zh) | 曲普瑞林口颊膜及其制备方法 | |
| WO2025252204A1 (en) | Amorphous solid dispersions of a braf inhibitor | |
| CN110384669A (zh) | 一种司美替尼及其衍生物的新剂型及制备方法 | |
| KR20250136925A (ko) | 면역 질환 또는 장애를 예방 또는 치료하는 방법에 사용하기 위한 마크로라이드 |